

## Public Declaration of Interests The European Patients' Forum Board Members

### **Public Declaration of Interests**

I,

Name: Nikos Dedes

Organisation: Greek Patient Association

Country: Greece

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in healthcare industries are those listed below:

Please indication N/A (Not applicable) as appropriate

#### 2.1 Employment in the healthcare industry

| Period | Company | Job title |
|--------|---------|-----------|
| none   |         |           |

#### 2.2 Consultancy

• Consultancy to a company shall mean: any activity where the board member provides advice (including training on a one to one basis) to a company regardless of contractual arrangements or any form of remuneration.

| Period | Company | Subject Matter |  |
|--------|---------|----------------|--|
| none   |         |                |  |

2.3. Consultancy/advisory role on patient-related activities in the last year

• The board member provides advice or participates in consultations regarding patient-related activities of a company that are strictly non-commercial (e.g. educational seminars, preparation and participation in patient meetings/trainings, development of non-product patient specific materials, participation in trainings of a company staff on patient-centricity etc.)

European Patients' Forum • Chaussée d'Etterbeek, 180 • 1040 Brussels • Belgium Office Phone Number: +32 (0) 2 280 23 34 • Email: info@eu-patient.eu • www.eu-patient.eu



#### Strategic

| Period | Company | Subject Matter |
|--------|---------|----------------|
| none   |         |                |

#### Advisory Role

Strategic advisory role for a company shall mean: any activity where the board members participating (with a right to vote/influence the outputs) in a(n) (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the (future) strategy, direction and development activities of a healthcare company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration.

| Period | Company | Product | Therapeutic Indication |
|--------|---------|---------|------------------------|
| none   |         |         |                        |

#### 2.4 Financial Interests

| Period | Company | Subject Matter |
|--------|---------|----------------|
| none   |         |                |

#### 2.5 Principal Investigator

| Period | Company | Subject Matter |
|--------|---------|----------------|
| none   |         |                |

#### 2.6 Investigator

| Period | Company | Subject Matter |
|--------|---------|----------------|
| none   |         |                |

# 2.7 Grant / Funding to Organisation /Institution in 2022 (This is the organisation which nominated you to become a member of EPF)

| Company                      | Subject Matter and amount                             |
|------------------------------|---|
| GlaxoSmithKline<br>Hellas SA | European Day of Patients' Rights 2022 amount: 6200,00 |
| AstraZeneca SA               | European Day of Patients' Rights 2022 amount: 3720,00 |



| Janssen-Cilag SA             | European Day of Patients' Rights 2022 amount: 3720,00  |
|------------------------------|--|
| Ipsen Hellas                 | European Day of Patients' Rights 2022 amount: 3720,00  |
| Gilead Sciences<br>Hellas    | European Day of Patients' Rights 2022 amount: 6200,00  |
| Chiesi                       | European Day of Patients' Rights 2022 amount: 2480,00  |
| Sanofi                       | European Day of Patients' Rights 2022 amount: 3720,00  |
| Boehringer                   | European Day of Patients' Rights 2022 amount: 3720,00  |
| Genesis Pharma               | European Day of Patients' Rights 2022 amount: 6200,00  |
| Swixx                        | Patients' Summit 2022 amount: 2000,00  |
| Roche Diagnostics            | European Day of Patients' Rights 2022 amount: 3100,00  |
| GlaxoSmithKline<br>Hellas SA | Patients' Summit 2022 amount: 3000,00  |
| Sanofi                       | Patients' Summit 2022 amount: 3000,00  |
| Abbvie                       | Patients' Summit 2022 amount: 2500,00  |
| Janssen                      | Patients' Summit 2022 amount: 3720,00  |
| ELPEN                        | Patients' Summit 2022 amount: 2000,00  |
| VIANEX                       | Patients' Summit 2022 amount: 3000,00  |
| Bayer                        | Patients' Summit 2022 amount: 8680,00  |
| TAKEDA                       | European Day of Patients' Rights 2022 amount: 6200,00  |
| ΕΛΠΕΝ                        | European Day of Patients' Rights 2022 amount: 2480,00  |
| ROCHE                        | European Day of Patients' Rights 2022 amount: 3100,00  |
| Pharmasave Lilly             | European Day of Patients' Rights 2022 amount: 3720,00  |
| WinMedica                    | European Day of Patients' Rights 2022 amount: 3000,00  |
| Pharmasave Lilly             | European Day of Patients' Rights 2022 amount: 2000,00  |
| Pfizer                       | Study to evaluate the role of patient representatives in health policy decision-making in Greece with an emphasis on the health technology assessment process amount: 31000,00 |
| Novartis                     | 11st Panhellenic Patients Conference amount: 6200,00   |
| GlaxoSmithKline<br>Hellas SA | 11st Panhellenic Patients Conference amount: 6200,00   |
| AstraZeneca                  | 11st Panhellenic Patients Conference amount: 11160,00  |
| Medtronic                    | 11st Panhellenic Patients Conference amount: 6200,00   |
| BMS                          | 11st Panhellenic Patients Conference amount: 6324,00   |



| VIANEX   | 11st Panhellenic Patients Conference amount: 8680,00  |  |
|--|---|--|
| Janssen  | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Pfizer   | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Sanofi   | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Gilead   | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| UCB  | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Boehringer   | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Chiesi   | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Bayer  | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Astellas   | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Genesis  | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Amgen  | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Winmedica  | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Novo Nordisk   | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Pharmaserve Lilly  | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| Takeda   | 11st Panhellenic Patients Conference amount: 3100,00  |  |
| MSD  | 11st Panhellenic Patients Conference amount: 11160,00 |  |
| ΕΛΠΕΝ  | 11st Panhellenic Patients Conference amount: 4960,00  |  |
| ROCHE  | 11st Panhellenic Patients Conference amount: 6200,00  |  |
| TIMA foundation  | "Together" Helpline 11132 amount: 6148,23             |  |
| - Kennel Andreas - Andreas | 1   |  |

#### 2.8 Close Family Member Interest

| Period | Company | Interest |
|--------|---------|----------|
| none   |         |          |

#### 2.9 Any Other Interests or Facts

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EPF website.



| Full Name | Nikos Dedes   |
|-----------|---------------|
| Date      | 31 March 2023 |